Drugs / TQH3821
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05380934 | May 2022 → May 2023 | rheumatoid arthritis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05849727 | Aug 2023 → Jan 2025 | rheumatoid arthritis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQH3821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05380934 ↗ |
| Known as | TQH3821 tablets | “TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.” NCT05380934 ↗ |
| Action | Inhibit | “inhibitory activity against IRAK4 kinase” NCT05380934 ↗ |
| Route | Oral | “Oral administration of TQH3821 tablets 200 mg, twice a day for 24 weeks.” NCT05849727 ↗ |
| Target | IRAK4 | “inhibitory activity against IRAK4 kinase” NCT05380934 ↗ |